Immunoscreening

Immunoscreening is a method of biotechnology used to detect a polypeptide produced from a cloned gene. The term encompasses several different techniques designed for protein identification, such as Western blotting, using recombinant DNA, and analyzing antibody-peptide interactions.[1]

Clones are screened for the presence of the gene product: the resulting protein. This strategy requires first that a gene library is implemented in an expression vector, and that antiserum to the protein is available. Radioactivity or an enzyme is coupled generally with the secondary antibody. The radioactivity/enzyme linked secondary antibody can be purchased commercially and can detect different antigens. In commercial diagnostics labs, labelled primary antibodies are also used.[2] The antigen-antibody interaction is used in the immunoscreening of several diseases.[3]

See also

References

  1. Razavi, Morteza; Pope, Matthew E.; Soste, Martin V.; Eyford, Brett A.; Jackson, Angela M.; Anderson, N. Leigh; Pearson, Terry W. (2011-02-01). "MALDI immunoscreening (MiSCREEN): a method for selection of anti-peptide monoclonal antibodies for use in immunoproteomics". Journal of Immunological Methods. 364 (1–2): 50–64. doi:10.1016/j.jim.2010.11.001. ISSN 1872-7905. PMC 3018550. PMID 21078325.
  2. Karam, James (November 26, 1990). Methods in Nucleic Acids Research. CRC Press. p. 309. ISBN 0849353114.
  3. Mukerjee S, McKnight ME, Glassy MC. Immunoscreening protocols for the identification of clinically useful antibodies and antigens. Expert Opin Investig Drugs. 1998 Mar;7(3):373-89. doi: 10.1517/13543784.7.3.373. PMID 15991979.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.